profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
Published 4 years ago • 855 plays • Length 9:59Download video MP4
Download video MP3
Similar videos
-
10:21
profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
-
3:05
mcrpc: the importance of genomic profiling
-
4:30
profound: olaparib for hrr mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
4:09
updates in urological cancer presented at esmo 2020
-
8:51
esmo 2020 expert video report on precision medicine in prostate cancer
-
4:17
opaganib for mcrpc after abiraterone or enzalutamide
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
16:07
profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
1:19
highlights in prostate cancer from esmo
-
6:39
profound: parp inhibitor olaparib compared with new hormonal agents in advanced castration resis...
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc